Ratings Huaxia Eye Hospital Group Co.,Ltd.

Equities

301267

CNE100005WL5

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
25.49 ^CNY	+1.51%		-2.93%	-20.57%

Apr. 30	Huaxia Eye Hospital Group Co.,Ltd. agreed to acquire Xiamen Huaxia Juxin No. 1 Investment Consulting Co., Ltd. from Xiamen Huaxia Juxin No. 1 Investment Partnership Enterprise (Limited Partnership) and Nanjing Xinke Dongzheng 01 Venture Capital Partnership Enterprise (Limited Partnership) for approximately CNY 500 million.	CI
Apr. 26	Huaxia Eye Hospital Group Co.,Ltd. Proposes Final Cash Dividend for 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The firm trades with high earnings multiples: 26.69 times its 2024 earnings per share.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HUAXIA EYE HOSPITAL GROUP CO.,LTD.	-20.57%	2.95B		-
TOPCHOICE MEDICAL CO., INC.	-16.01%	2.84B		C+
AGILON HEALTH, INC.	-56.89%	2.22B		C-
AIRSCULPT TECHNOLOGIES, INC.	-37.78%	268M		-
EUROEYES INTERNATIONAL EYE CLINIC LIMITED	+5.57%	235M		-
MEDSCI HEALTHCARE HOLDINGS LIMITED	-40.04%	196M	-	-
AESTHETIC CONNECT	-36.31%	110M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes